Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update

Conference Call to be held Friday, March 31, at 9:00am Eastern TimeATLANTA, March 24, 2023 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report fourth quarter and full year 2022 financial results on Friday, March 31, 2023, before the market opens. Management will host a conference call at 9:00 AM ET the same day, to review financial results and provide an update on corporate developments. Following management’s formal remarks, there will be a question-and-answer session. Participants are asked to pre-register for the call. Please note that registered participants will receive their dial-in number upon registration and will dial directly into the call without delay. Those without Internet access or who are unable to pre-register may dial in by calling 1-844-839-2190 (domestic) or 1-412-717-9583 (international). All callers should dial-in approximately 10 minutes prior to the scheduled start time and ask to be joined into the Alimera Sciences call. The conference call will also be available through a live webcast, which is also available through the company’s website. A webcast replay of the call will be available approximately one hour after the end of the call through July 1, 2023. The webcast replay can be accessed through the above links or by calling 1-877-344-7529 (domestic) or 1-412-317-0088 (international) and using access code 5931698. The telephonic replay will be available until April 14, 2023. About Alimera Sciences, Inc.Alimera Sciences is a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit www.alimerasciences.com. For press inquiries:For investor inquiries:Jules AbrahamScott Gordonfor Alimera Sciencesfor Alimera Sciences917-885-7378 [email protected]@coreir.com